Nanocząstki o wysokiej zawartości boru jako potencjalne nośniki w terapii borowo-neutronowej*
References
- Al-Madhoun A.S., Johnsamuel J., Barth R.F., Tjarks W., Eriksson S.: Evaluation of human thymidine kinase 1 substrates as new candidates for boron neutron capture therapy. Cancer Res., 2004; 64: 6280–6286
- Archambeau J.O.: The effect of increasing exposures of the 10B(n,α)7Li reaction on the skin of man. Radiology, 1970; 94: 178–187
- Barth R.F., Coderre J.A., Vicente M.G., Blue T.E.: Boron neutron capture therapy of cancer: Current status and future prospects. Clin. Cancer. Res., 2005; 11: 3987–4002
- Barth R.F., Kabalka G.W., Yang W., Huo T., Nakkula R.J., Shaikh A.L., Haider S.A., Chandra S.: Evaluation of unnatural cyclic amino acids as boron delivery agents for treatment of melanomas and gliomas. Appl. Radiat. Isot., 2014; 88: 38–42
- Barth R.F., Mi P., Yang W.: Boron delivery agents for neutron capture therapy of cancer. Cancer Commun., 2018; 38: 35
- Barth R.F., Yang W., Nakkula R.J., Byun Y., Tjarks W., Wu L.C., Binns P.J., Riley K.J.: Evaluation of TK1 targeting carboranyl thymidine analogs as potential delivery agents for neutron capture therapy of brain tumors. Appl. Radiat. Isot., 2015; 106: 251–255
- Barth R.F., Yang W., Rotaru J.H., Moeschberger M.L., Joel D.D., Nawrocky M.M., Goodman J.H., Soloway A.H..: Boron neutron capture therapy of brain tumors: Enhanced survival following intracarotid injection of either sodium borocaptate or boronophenylalanine with or without blood–brain barrier disruption. Cancer Res., 1997; 57: 1129–1136
- Bertrand N., Wu J., Xu X., Kamaly N., Farokhzad O.C.: Cancer nanotechnology: The impact of passive and active targeting in the era of modern cancer biology. Adv. Drug Deliv. Rev. 2014; 66: 2–25
- Bhimanapati G.R., Glavin N.R. Robinson J.A.: 2D boron nitride: Synthesis and applications. Semicond. Semimet., 2016; 95: 101–147
- Bortolussi S., Bakeine J.G., Ballarini F., Bruschi P., Gadan M. A., Protti N., Stella S., Clerici A., Ferrari C., Cansolino L., Zonta C., Zonta A., Nano R., Altieri S.: Boron uptake measurements in a rat model for Boron Neutron Capture Therapy of lung tumours. Appl. Radiat. Isot., 2011; 69: 394–398
- Capuani S., Gili T., Bozzali M., Russo S., Porcari P., Cametti C., Muolo M., D’Amore E., Maraviglia B., Lazzarino G., Pastore F.S.: Boronophenylalanine uptake in C6 glioma model is dramatically increased by L-DOPA preloading. Appl. Radiat. Isot., 2009; 67: S34–S36
- Chen X., Wu P., Rousseas M., Okawa D., Gartner Z., Zettl A., Bertozzi C.R.: Boron nitride nanotubes are noncytotoxic and can be functionalized for interaction with proteins and cells. J. Am. Chem. Soc., 2009; 131: 890–891
- Ciofani G., Danti S., D’Alessandro D., Moscato S., Menciassi A.: Assessing cytotoxicity of boron nitride nanotubes: Interference with the MTT assay. Biochem. Biophys. Res. Commun., 2010; 394: 405–411
- Ciofani G., Danti S., Genchi G.G., Mazzolai B., Mattoli V.: Boron nitride nanotubes: Biocompatibility and potential spill-over in nanomedicine. Small., 2013; 9: 1672–1685
- Ciofani G., Raffa V., Menciassi., Cuschieri A.: Cytocompatibility, interactions, and uptake of polyethyleneimine-coated boron nitride nanotubes by living cells: Confirmation of their potential for biomedical applications. Biotechnol. Bioeng., 2008; 101: 850–858
- Coderre J.A., Glass J.D., Fairchild R.G., Micca P.L., Fand I., Joel D.D.: Selective delivery of boron by the melanin precursor analogue p-boronophenylalanine to tumors other than melanoma. Cancer Res., 1990; 50: 138–141
- Cui D., Tian F., Ozkan C.S., Wang M., Gao H.: Effect of single wall carbon nanotubes on human HEK293 cells. Toxicol. Lett., 2005; 155: 73–85
- Dahlström M., Capala J., Lindström P., Wasteson Å., Lindström A.: Accumulation of boron in human malignant glioma cells in vitro is cell type dependent. J. Neuro-Oncol., 2004; 68: 199–205
- Dobrzyński L.: Spowalnianie neutronów w moderatorze. W: Podstawy Fizyki Reaktorów Jądrowych, red.: L. Dobrzyński. Świerk 2013, 60–61
- Duong N.M., Glushkov E., Chernev A., Navikas V., Comtet J., Nguyen M.A., Toth M., Radenovic A., Tran T.T., Aharonovich I.: Facile production of hexagonal boron nitride nanoparticles by cryogenic exfoliation. Nano. Lett., 2019: 19: 5417–5422
- Feng B., Tomizawa K., Michiue H., Miyatake S., Han X.J., Fujimura A., Seno M., Kirihata M., Matsui H.: Delivery of sodium borocaptate to glioma cells using immunoliposome conjugated with anti-EGFR antibodies by ZZ-His. Biomaterials, 2009; 30: 1746–1755
- Ferreira T.H., Miranda M.C., Rocha Z., Leal A.S., Gomes D.A., Sousa E.M.: An assessment of the potential use of BNNTs for Boron Neutron Capture Therapy. Nanomaterials, 2017; 7: 82
- Gao Z., Horiguchi Y., Nakai K., Matsumura A., Suzuki M., Ono K., Nagasaki Y:. Use of boron cluster-containing redox nanoparticles with ROS scavenging ability in boron neutron capture therapy to achieve high therapeutic efficiency and low adverse effects. Biomaterials, 2016; 104: 201–212
- Gonzalez-Ortiz D., Salameh C., Bechelany M., Miele P.: Nanostructured boron nitride – based materials: Synthesis and applications. Mater. Today Adv., 2020; 8: 100107
- Goodman J.H., Yang W., Barth R.F., Gao Z., Boesel C.P., Staubus A.E., Gupta N., Gahbauer R.A., Adams D.M., Gibson C.R., Ferketich A.K., Moeschberger M.L., Soloway A.H., Carpenter D.E., Albertson B.J. i wsp.: Boron neutron capture therapy of brain tumors: Biodistribution, pharmacokinetics, and radiation dosimetry sodium borocaptate in patients with gliomas. Neurosurgery, 2000; 47: 608–621
- Hatanaka H., Nakagawa Y.: Clinical results of long-surviving brain tumor patients who underwent boron neutron capture therapy. Int. J. Radiat. Oncol. Biol. Phys., 1994; 28: 1061–1066
- Hiratsuka J., Kamitani N., Tanaka R., Tokiya R., Yoden E., Sakurai Y., Suzuki M.: Long-term outcome of cutaneous melanoma patients treated with boron neutron capture therapy (BNCT). J. Radiat. Res., 2020; 61: 945–951
- Horváth L., Magrez A., Golberg D., Zhi C., Bando Y., Smajda R., Horváth E., Forró L., Schwaller B.: In vitro investigation of the cellular toxicity of boron nitride nanotubes. ACS Nano, 2011; 5: 3800–3810
- Ichikawa H., Taniguchi E., Fujimoto T., Fukumori Y.: Biodistribution of BPA and BSH after single, repeated and simultaneous administrations for neutron-capture therapy of cancer. Appl. Radiat. Isot., 2009; 67: S111–S114
- Ishikawa Y., Shimizu Y., Sasaki T., Koshizaki N.: Boron carbide spherical particles encapsulated in graphite prepared by pulsed laser irradiation of boron in liquid medium. Appl. Phys. Lett., 2007; 91: 161110
- Itoh T., Tamura K., Ueda H., Tanaka T., Sato K., Kuroda R., Aoki S.: Design and synthesis of boron containing monosaccharides by the hydroboration of D-glucal for use in boron neutron capture therapy (BNCT). Bioorg. Med. Chem., 2018; 26: 5922–5933
- Iwagami T., Ishikawa Y., Koshizaki N., Yamamoto N., Tanaka H., Masunaga S., Sakurai Y., Kato I., Iwai S., Suzuki M., Yura Y.: Boron carbide particle as a boron compound for Boron Neutron Capture Therapy. J. Nucl. Med. Radiat. Ther., 2014; 5: 2
- Kabalka G.W., Shaikh A.L., Barth R.F., Huo T., Yang W., Gordnier P.M., Chandra S.: Boronated unnatural cyclic amino acids as potential delivery agents for neutron capture therapy. Appl. Radiat. Isot., 2011; 69: 1778–1781
- Kabalka G.W., Yao M.L., Marepally S.R., Chandra S.: Biological evaluation of boronated unnatural amino acids as new boron carriers. Appl. Radiat. Isot., 2009; 67: S374–S379
- Kageji T., Nagahiro S., Mizobuchi Y., Matsuzaki K., Nakagawa Y., Kumada H.: Boron neutron capture therapy (BNCT) for newly-diagnosed glioblastoma: Comparison of clinical results obtained with BNCT and conventional treatment. J. Med. Invest., 2014; 61: 254–263
- Kato I., Fujita Y., Maruhashi A., Kumada H., Ohmae M., Kirihata M., Imahori Y., Suzuki M., Sakrai Y., Sumi T., Iwai S., Nakazawa M., Murata I., Miyamaru H., Ono K.: Effectiveness of boron neutron capture therapy for recurrent head and neck malignancies. Appl. Radiat. Isot., 2009; 67: S37–S42
- Kato T., Hirose K., Tanaka H., Mitsumoto T., Motoyanagi T., Arai K., Harada T., Takeuchi A., Kato R., Yajima S., Takai Y.: Design and construction of an accelerator-based boron neutron capture therapy (AB-BNCT) facility with multiple treatment rooms at the Southern Tohoku BNCT Research Center. Appl. Radiat. Isot., 2020; 156: 108961
- Kaur M., Singh P., Singh K., Gaharwar U.S., Meena R., Kumar M., Nakagawa F., Wu S., Suzuki M., Nakamura H., Kumar A.: Boron nitride (10BN) a prospective material for treatment of cancer by boron neutron capture therapy (BNCT). Mater. Lett., 2020; 259: 126832
- Kawabata S., Yang W., Barth R.F., Wu G., Huo T., Binns P.J., Riley K.J., Ongayi O., Gottumukkala V., Vicente M.G.: Convection enhanced delivery of carboranylporphyrins for neutron capture therapy of brain tumors. J. Neuro-Oncol., 2011; 103: 175–185
- Kimura Y., Ariyoshi Y., Shimahara M., Miyatake S., Kawabata S., Ono K., Suzuki M., Maruhashi A.: Boron neutron capture therapy for recurrent oral cancer and metastasis of cervical lymph node. Appl. Radiat. Isot., 2009; 67: S47–S49
- Kiyanagi Y., Sakurai Y., Kumada H., Tanaka H.: Status of accelerator-based BNCT projects worldwide. AIP Conf. Proc., 2019; 2160: 050012
- Kullberg E.B., Wei Q., Capala J., Giusti V., Malmström P.U., Gedda L.: EGF-receptor targeted liposomes with boronatedacridine: Growth inhibition of cultured glioma cells after neutron irradiation. Int. J. Radiat. Biol., 2005; 81: 621–629
- Kumada H., Naito F., Hasegawa K., Kobayashi H., Kurihara T., Takada K., Onishi T., Sakurai H., Matsumura A., Sakae T.: Development of LINAC-based neutron source for Boron Neutron Capture Therapy in University of Tsukuba. Plasma Fusion Res., 2018; 13: 2406006
- Lai C.H., Lin Y.C., Chou F.I., Liang C.F., Lin E.W., Chuang Y.J., Lin C.C.: Design of multivalent galactosyl carborane as a targeting specific agent for potential application to boron neutron capture therapy. Chem. Commun., 2012; 48: 612–614
- Lam C.W., James J.T., McCluskey R., Hunter R.L.: Pulmonary toxicity of single-wall carbon nanotubes in mice 7 and 90 days after intratracheal instillation. Toxicol. Sci., 2004; 77: 126–134
- Lee C.H., Zhang D., Yap Y.K.: Functionalization, dispersion, and cutting of boron nitride nanotubes in water. J. Phys. Chem. C, 2012; 116: 1798–1804
- Luderer M.J., de la Puente P., Azab A.K.: Advancements in tumor targeting strategies for Boron Neutron Capture Therapy. Pharm. Res., 2015; 32: 2824–2836
- Luderer M.J., Muz B., Alhallak K., Sun J., Wasden K., Guenthner N., de la Puente P., Federico C., Azab A.K.: Thermal sensitive liposomes improve delivery of boronated agents for Boron Neutron Capture Therapy. Pharm. Res., 2019; 36: 144
- Masunaga S., Kasaoka S., Maruyama K., Nigg D., Sakurai Y., Nagata K., Suzuki M., Kinashi Y., Maruhashi A., Ono K.: The potential of transferrin-pendant-type polyethyleneglycol liposomes encapsulating decahydrodecaborate-10B (GB-10) as 10B-carriers for boron neutron capture therapy. Int. J. Radiat. Oncol. Biol. Phys., 2006; 66: 1515–1522
- Mattson M.P., Haddon R.C., Rao A.M.: Molecular functionalization of carbon nanotubes and use as substrates for neuronal growth. J. Mol. Neurosci., 2000; 14: 175–182
- Mi P., Yanagie H., Dewi N., Yen H.C., Liu X., Suzuki M., Sakurai Y., Ono K., Takahashi H., Cabral H., Kataoka K., Nishiyama N.: Block co-polymer boron cluster conjugate for effective boron neutron capture therapy of solid tumors. J. Control. Release, 2017; 254: 1–9
- Michiue H., Sakurai Y., Kondo N., Kitamatsu M., Bin F., Nakajima K., Hirota Y., Kawabata S., Nishiki T., Ohmori I., Tomizawa K., Miyatake S., Ono K., Matsui H.: The acceleration of boron neutron capture therapy using multi-linked mercaptoundecahydrododecaborate (BSH) fused cell-penetrating peptide. Biomaterials, 2014; 35: 3396–3405
- Mirzaei H.R., Sahebkar A., Salehi R., Nahand J.S., Karimi E., Jaafari M.R., Mirzaei H.: Boron neutron capture therapy: Moving toward targeted cancer therapy. J. Cancer Res. Ther., 2016; 12: 520–525
- Mishima Y., Honda C., Ichihashi M., Obara H., Hiratsuka J., Fukuda H., Karashima H., Kobayashi T., Kanda K., Yoshino K.: Treatment of malignant melanoma by single thermal neutron capture therapy with melanoma-seeking 10B-compound. Lancet, 1989; 2: 388–389
- Miyatake S.I., Kawabata S., Hiramatsu R., Kuroiwa T., Suzuki M., Ono K.: Boron Neutron Capture Therapy of malignant gliomas. Prog. Neurol. Surg., 2018; 32: 48–56
- Miyatake S.I., Kawabata S., Kajimoto Y., Aoki A., Yokoyama K., Yamada M., Kuroiwa T., Tsuji M., Imahori Y., Kirihata M., Sakurai Y., Masunaga S.I., Nagata K., Maruhashi A., Ono K.: Modified boron neutron capture therapy for malignant gliomas performed using epithermal neutron and two boron compounds with different accumulation mechanisms: An efficacy study based on findings on neuroimages. J. Neurosurg., 2005; 103: 1000–1009
- Mortensen M.W., Sørensen P.G., Björkdahl O., Jensen M.R., Gundersen H.J., Bjørnholm T.: Preparation and characterization of boron carbide nanoparticles for use as a novel agent in T cell-guided boron neutron capture therapy. Appl. Radiat. Isot., 2006; 64: 315–324
- Moss R.L.: Critical review, with an optimistic outlook, on Boron Neutron Capture Therapy (BNCT). Appl. Radiat. Isot., 2014; 88: 2–11
- Naito F.: Introduction to accelerators for boron neutron capture therapy. Ther. Radiol. Oncol., 2018; 2: 54
- Nakagawa Y., Pooh K., Kobayashi T., Kageji T., Uyama S., Matsumura A., Kumada H.: Clinical review of the Japanese experience with boron neutron capture therapy and a proposed strategy using epithermal neutron beams. J. Neuro-Oncol., 2003; 62: 87–99
- Nakamura H., Koganei H., Miyoshi T., Sakurai Y., Ono K., Suzuki M.: Antitumor effect of boron nitride nanotubes in combination with thermal neutron irradiation on BNCT. Bioorg. Med. Chem. Lett., 2015; 25: 172–174
- Nakamura S., Imamichi S., Masumoto K., Ito M., Wakita A., Okamoto H., Nishioka S., Iijima K., Kobayashi K., Abe Y., Igaki H., Kurita K., Nishio T., Masutani M., Itami J.: Evaluation of radioactivity in the bodies of mice induced by neutron exposure from an epi-thermal neutron source of an accelerator-based boron neutron capture therapy system. Proc. Jpn. Acad. Ser. B Phys. Biol. Sci., 2017; 93: 821–831
- Nedunchezhian K., Aswath N., Thiruppathy M., Thirugnanamurthy S.: Boron Neutron Capture Therapy – A literature review. J. Clin. Diagn. Res., 2016; 10: ZE01–ZE04
- Nemoto H., Cai J., Asao N., Iwamoto S., Yamamoto Y.: Synthesis and biological properties of water-soluble p-boronophenylalanine derivatives. Relationship between water solubility, cytotoxicity, and cellular uptake. J. Med. Chem., 1995; 38: 1673–1678
- Petersen M.S., Petersen C.C., Agger R., Sutmuller M., Jensen M.R., Sørensen P.G., Mortensen M.W., Hansen T., Bjørnholm T., Gundersen H.J., Huiskamp R., Hokland M.: Boron nanoparticles inhibit tumour growth by boron neutron capture therapy in the murine B16-OVA model. Anticancer Res., 2008; 28: 571–576
- Radomski J., Rećko W.M., Ketling-Szemley M.: Własności azotku boru i metody jego otrzymywania. Wydawnictwa Przemysłu Maszynowego “WEMA”. Warszawa 1980
- Ryashentsev D.S., Belenkov E.A.: New BN polymorphs with two-dimensional structure. IOP Conf. Ser.: Mater. Sci. Eng., 2019; 537: 022060
- Seki R., Wakisaka Y., Morimoto N., Takashina M., Koizumi M., Toki H., Fukuda M.: Physics of epi-thermal boron neutron capture therapy (epi-thermal BNCT). Radiol. Phys. Technol., 2017; 10: 387–408
- Şen Ö., Emanet M., Çulha M.: One-step synthesis of hexagonal boron nitrides, their crystallinity and biodegradation. Front. Bioeng. Biotechnol., 2018; 6: 83
- Shvedova A.A., Castranova V., Kisin E.R., Schwegler-Berry D., Murray A.R., Gandelsman V.Z., Maynard A., Baron P.: Exposure to carbon nanotube material: Assessment of nanotube cytotoxicity using human keratinocyte cells. J. Toxicol. Environ. Health A, 2003; 66: 1909–1926
- Singh B., Kaur G., Singh P., Singh K. Kumar B., Vij A., Kumar M., Bala R., Meena R., Singh A., Thakur A., Kumar A.: Nanostructured boron nitride with high water dispersibility for Boron Neutron Capture Therapy. Sci. Rep., 2016; 6: 35535
- Slatkin D.N.: A history of boron neutron capture therapy of brain tumours. Postulation of a brain radiation dose tolerance limit. Brain, 1991; 114: 1609–1629
- Suzuki M.: Boron neutron capture therapy (BNCT): A unique role in radiotherapy with a view to entering the accelerator-based BNCT era. Int. J. Clin. Oncol., 2020; 25: 43–50
- Suzuki M., Masunaga S.I., Kinashi Y., Takagaki M., Sakurai Y., Kobayashi T., Ono K.: The effects of boron neutron capture therapy on liver tumors and normal hepatocytes in mice. Jpn. J. Cancer Res., 2000; 91: 1058–1064
- Tajes M., Ramos-Fernández E., Weng-Jiang X., Bosch-Morató M., Guivernau B., Eraso-Pichot A., Salvador B., Fernàndez-Busquets X., Roquer J., Muñoz F.J.: The blood-brain barrier: Structure, function and therapeutic approaches to cross it. Mol. Membr. Biol., 2014; 31: 152–167
- Tsuji T., Yoshitomi H., Ishikawa Y., Koshizaki N., Suzuki M., Usukura J.: A method to selectively internalize submicrometer boron carbide particles into cancer cells using surface transferrin conjugation for developing a new boron neutron capture therapy agent. J. Exp. Nanosci., 2020; 15: 1–11
- Türkez H., Arslan M.E., Sönmez E., Geyikoğlu F., Açıkyıldız M., Tatar A.: Microarray assisted toxicological investigations of boron carbide nanoparticles on human primary alveolar epithelial cells. Chem. Biol. Interact., 2019; 300: 131–137
- Vos M.J., Turowski B., Zanella F.E., Paquis P., Siefert A., Hideghéty K., Haselsberger K., Grochulla F., Postma T.J., Wittig A., Heimans J.J., Slotman B.J., Vandertop W.P., Sauerwein W.: Radiologic findings in patients treated with boron neutron capture therapy for glioblastoma multiforme within EORTC trial 11961. Int. J. Radiat. Oncol. Biol. Phys., 2005; 61: 392–399
- Warheit D.B., Laurence B.R., Reed K.L., Roach D.H., Reynolds G.A., Webb T.R.: Comparative pulmonary toxicity assessment of single-wall carbon nanotubes in rats. Toxicol. Sci., 2004; 77: 117–125
- Weng Q., Wang B., Wang X., Hanagata N., Li X., Liu D., Wang X., Jiang X., Bando Y., Golberg D.: Highly water-soluble, porous, and biocompatible boron nitrides for anticancer drug delivery. ACS Nano, 2014; 8: 6123–6130
- Wittig A., Sauerwein W.A., Coderre J.A.: Mechanisms of transport of p-borono-phenylalanine through the cell membrane in vitro. Radiat. Res., 2000; 153: 173–180
- Wittig A., Stecher-Rasmussen F., Hilger R.A., Rassow J., Mauri P., Sauerwein W.: Sodium mercaptoundecahydro-closo-dodecaborate (BSH), a boron carrier that merits more attention. Appl. Radiat. Isot., 2011; 69: 1760–1764
- Wu G., Yang W., Barth R.F., Kawabata S., Swindall M., Bandyopadhyaya A.K., Tjarks W., Khorsandi B., Blue T.E., Ferketich A.K., Yang M., Christoforidis G.A., Sferra T.J., Binns P.J., Riley K.J. i wsp.: Molecular targeting and treatment of an epidermal growth factor receptor-positive glioma using boronated cetuximab. Clin. Cancer Res., 2007; 13: 1260–1268
- Yanagië H., Tomita T., Kobayashi H., Fujii Y., Takahashi T., Hasumi K., Nariuchi H., Sekiguchi M.: Application of boronated anti-CEA immunoliposome to tumour cell growth inhibition in in vitro boron neutron capture therapy model. Br. J. Cancer, 1991; 63: 522–526
- Yang W., Barth R.F., Wu G., Tjarks W., Binns P., Riley K.: Boron neutron capture therapy of EGFR or EGFRvIII positive gliomas using either boronated monoclonal antibodies or epidermal growth factor as molecular targeting agents. Appl. Radiat. Isot., 2009; 67: S328–S331
- Yang W., Wu G., Barth R.F., Swindall M.R., Bandyopadhyaya A.K., Tjarks W., Tordoff K., Moeschberger M., Sferra T.J., Binns P.J., Riley K.J., Ciesielski M.J., Fenstermaker R.A., Wikstrand C.J.: Molecular targeting and treatment of composite EGFR and EGFRvIII-positive gliomas using boronated monoclonal antibodies. Clin. Cancer Res., 2008; 14: 883–891
- Yinghuai Z., Peng A.T., Carpenter K., Maguire J.A., Hosmane N.S., Takagaki M.: Substituted carborane-appended water-soluble single-wall carbon nanotubes: New approach to Boron Neutron Capture Therapy drug delivery. J. Am. Chem. Soc., 2005; 127: 9875–9880
- Yokoyama K., Miyatake S., Kajimoto Y., Kawabata S., Doi A., Yoshida T., Asano T., Kirihata M., Ono K., Kuroiwa T.: Pharmacokinetic study of BSH and BPA in simultaneous use for BNCT. J. Neuro-Oncol., 2006; 78: 227–232
- Zhuo J.C., Cai J., Soloway A.H., Barth R.F., Adams D.M., Ji W., Tjarks W.: Synthesis and biological evaluation of boron-containing polyamines as potential agents for neutron capture therapy of brain tumors. J. Med. Chem., 1999; 42: 1282–1292
DOI: https://doi.org/10.5604/01.3001.0014.7760 | Journal eISSN: 1732-2693
Language: English
Page range: 122 - 132
Submitted on: Nov 12, 2020
Accepted on: Dec 29, 2020
Published on: Feb 26, 2021
Published by: Hirszfeld Institute of Immunology and Experimental Therapy
In partnership with: Paradigm Publishing Services
Publication frequency: 1 times per year
Related subjects:
© 2021 Anna Wróblewska, Bożena Szermer-Olearnik, Elżbieta Pajtasz-Piasecka, published by Hirszfeld Institute of Immunology and Experimental Therapy
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.